lifestyle.clientim.com

Author: Eton Pharmaceuticals

Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

April 27, 2026
Eton Pharmaceuticals Announces CFO Succession Plan

April 16, 2026
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

March 19, 2026
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026

March 3, 2026
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

March 2, 2026
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution

February 25, 2026
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th

February 22, 2026
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

February 2, 2026